Cargando…
Multi-omics characterization and validation of invasiveness-related molecular features across multiple cancer types
BACKGROUND: Tumor invasiveness reflects many biological changes associated with tumorigenesis, progression, metastasis, and drug resistance. Therefore, we performed a systematic assessment of invasiveness-related molecular features across multiple human cancers. MATERIALS AND METHODS: Multi-omics da...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995758/ https://www.ncbi.nlm.nih.gov/pubmed/33766047 http://dx.doi.org/10.1186/s12967-021-02773-x |
_version_ | 1783669975677927424 |
---|---|
author | Bi, Guoshu Liang, Jiaqi Zheng, Yuansheng Li, Runmei Zhao, Mengnan Huang, Yiwei Zhan, Cheng Xu, Songtao Fan, Hong |
author_facet | Bi, Guoshu Liang, Jiaqi Zheng, Yuansheng Li, Runmei Zhao, Mengnan Huang, Yiwei Zhan, Cheng Xu, Songtao Fan, Hong |
author_sort | Bi, Guoshu |
collection | PubMed |
description | BACKGROUND: Tumor invasiveness reflects many biological changes associated with tumorigenesis, progression, metastasis, and drug resistance. Therefore, we performed a systematic assessment of invasiveness-related molecular features across multiple human cancers. MATERIALS AND METHODS: Multi-omics data, including gene expression, miRNA, DNA methylation, and somatic mutation, in approximately 10,000 patients across 30 cancer types from The Cancer Genome Atlas, Gene Expression Omnibus, PRECOG, and our institution were enrolled in this study. RESULTS: Based on a robust gene signature, we established an invasiveness score and found that the score was significantly associated with worse prognosis in almost all cancers. Then, we identified common invasiveness-associated dysregulated molecular features between high- and low-invasiveness score group across multiple cancers, as well as investigated their mutual interfering relationships thus determining whether the dysregulation of invasiveness-related genes was caused by abnormal promoter methylation or miRNA expression. We also analyzed the correlations between the drug sensitivity data from cancer cell lines and the expression level of 685 invasiveness-related genes differentially expressed in at least ten cancer types. An integrated analysis of the correlations among invasiveness-related genetic features and drug response were conducted in esophageal carcinoma patients to outline the complicated regulatory mechanism of tumor invasiveness status in multiple dimensions. Moreover, functional enrichment suggests the invasiveness score might serve as a predictive biomarker for cancer patients receiving immunotherapy. CONCLUSION: Our pan-cancer study provides a comprehensive atlas of tumor invasiveness and may guide more precise therapeutic strategies for tumor patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-021-02773-x |
format | Online Article Text |
id | pubmed-7995758 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-79957582021-03-30 Multi-omics characterization and validation of invasiveness-related molecular features across multiple cancer types Bi, Guoshu Liang, Jiaqi Zheng, Yuansheng Li, Runmei Zhao, Mengnan Huang, Yiwei Zhan, Cheng Xu, Songtao Fan, Hong J Transl Med Research BACKGROUND: Tumor invasiveness reflects many biological changes associated with tumorigenesis, progression, metastasis, and drug resistance. Therefore, we performed a systematic assessment of invasiveness-related molecular features across multiple human cancers. MATERIALS AND METHODS: Multi-omics data, including gene expression, miRNA, DNA methylation, and somatic mutation, in approximately 10,000 patients across 30 cancer types from The Cancer Genome Atlas, Gene Expression Omnibus, PRECOG, and our institution were enrolled in this study. RESULTS: Based on a robust gene signature, we established an invasiveness score and found that the score was significantly associated with worse prognosis in almost all cancers. Then, we identified common invasiveness-associated dysregulated molecular features between high- and low-invasiveness score group across multiple cancers, as well as investigated their mutual interfering relationships thus determining whether the dysregulation of invasiveness-related genes was caused by abnormal promoter methylation or miRNA expression. We also analyzed the correlations between the drug sensitivity data from cancer cell lines and the expression level of 685 invasiveness-related genes differentially expressed in at least ten cancer types. An integrated analysis of the correlations among invasiveness-related genetic features and drug response were conducted in esophageal carcinoma patients to outline the complicated regulatory mechanism of tumor invasiveness status in multiple dimensions. Moreover, functional enrichment suggests the invasiveness score might serve as a predictive biomarker for cancer patients receiving immunotherapy. CONCLUSION: Our pan-cancer study provides a comprehensive atlas of tumor invasiveness and may guide more precise therapeutic strategies for tumor patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-021-02773-x BioMed Central 2021-03-25 /pmc/articles/PMC7995758/ /pubmed/33766047 http://dx.doi.org/10.1186/s12967-021-02773-x Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Bi, Guoshu Liang, Jiaqi Zheng, Yuansheng Li, Runmei Zhao, Mengnan Huang, Yiwei Zhan, Cheng Xu, Songtao Fan, Hong Multi-omics characterization and validation of invasiveness-related molecular features across multiple cancer types |
title | Multi-omics characterization and validation of invasiveness-related molecular features across multiple cancer types |
title_full | Multi-omics characterization and validation of invasiveness-related molecular features across multiple cancer types |
title_fullStr | Multi-omics characterization and validation of invasiveness-related molecular features across multiple cancer types |
title_full_unstemmed | Multi-omics characterization and validation of invasiveness-related molecular features across multiple cancer types |
title_short | Multi-omics characterization and validation of invasiveness-related molecular features across multiple cancer types |
title_sort | multi-omics characterization and validation of invasiveness-related molecular features across multiple cancer types |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7995758/ https://www.ncbi.nlm.nih.gov/pubmed/33766047 http://dx.doi.org/10.1186/s12967-021-02773-x |
work_keys_str_mv | AT biguoshu multiomicscharacterizationandvalidationofinvasivenessrelatedmolecularfeaturesacrossmultiplecancertypes AT liangjiaqi multiomicscharacterizationandvalidationofinvasivenessrelatedmolecularfeaturesacrossmultiplecancertypes AT zhengyuansheng multiomicscharacterizationandvalidationofinvasivenessrelatedmolecularfeaturesacrossmultiplecancertypes AT lirunmei multiomicscharacterizationandvalidationofinvasivenessrelatedmolecularfeaturesacrossmultiplecancertypes AT zhaomengnan multiomicscharacterizationandvalidationofinvasivenessrelatedmolecularfeaturesacrossmultiplecancertypes AT huangyiwei multiomicscharacterizationandvalidationofinvasivenessrelatedmolecularfeaturesacrossmultiplecancertypes AT zhancheng multiomicscharacterizationandvalidationofinvasivenessrelatedmolecularfeaturesacrossmultiplecancertypes AT xusongtao multiomicscharacterizationandvalidationofinvasivenessrelatedmolecularfeaturesacrossmultiplecancertypes AT fanhong multiomicscharacterizationandvalidationofinvasivenessrelatedmolecularfeaturesacrossmultiplecancertypes |